Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 10, 2010, Pages 640-644

  Zhang, Qing Hua ^a   Yang, Jin ^a   He, Ying ^a   Liu, Fang ^b   Wang, Ji Ping ^c   Davey, Andrew K ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Antiviral agents; CAS 142217 69 4; Entecavir, dispersible tablets, food effects, pharmacokinetics

Indexed keywords

ENTECAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DISPERSIBLE TABLET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEEDING; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

EID: 78049330886     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296339     Document Type: Article

References (18)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-92.
2. Liang XF, Chen YS, Wang XJ, He X, Chen LJ, Wang J, et al. A study on the seroepidemiology of hepatitis B in Chinese population aged over 3-years old: the report from Chinese Center for Disease Control and Prevention. Chin J Epidemiol. 2005;26:655-8.
3. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009;122:3-4.
4. Data on 2006 seroepidemiological survey on HBV infection in China. Available from: http://www.moh.gov.cn
5. Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: A systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111-24.
6. Baraclude TM (entecavir) package insert. Princeton (NJ): Bristol-Myers Squibb Company. March 2005.
7. Santantonio T, Fasano M. Resistance profile of entecavir in patientswithchronic hepatitis B. Dig Liver Dis. 2008; Suppl 2: 11-5.
8. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44:1656-65.
9. Yao GB, Zhou XQ, Xu DZ, Wang BE, Ren H, Liu J, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int. 2007;1:373-81.
10. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in china from a perspective of the Chinese Social Security Program. Value Health. 2008;Suppl II:S11-22.
11. Yang J. Liu XQ, Liu XD. Development of abioavailability program-package 2.0. Chin J Clin Pharmacol. 2003;19:125-7.
12. Zhang DX, Fu YL, Gale JP, Aubry AF, Arnold ME. A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC-MS/MS. J Pharm Biomed Anal. 2008;49(4): 1027-33.
13. Hivid (zalcitabine) Nutley, NJ: Hoffman-La Roche. 2002. Physician's Desk Reference Electronic Library. 2004.
14. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118-30.
15. Damle BD, Yan JH, Behr D, O'Mara E, Nichola P, Kaul S, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002;42:419-27.
16. Fleisher D, Li C, Zhou YJ, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999;36:233-54.
17. Pao LH, Zhou SY, Cook C, Kararli T, Kirchhoff C, Truelove J, et al. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm Res. 1998;15(2):221-7.
18. Yan JH, Bifano M, Olsen S, Smith RA, Zhang DX, Grasela DM, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol. 2006;46:1250-8.